JAGX Jaguar Health, Inc.
Price Chart
Executive Summary
Jaguar Health entered into two capital-raising agreements with C/M Capital Partners on June 9, 2026: (1) an equity line of credit (ELOC) allowing the Company to sell up to $40M or 19.99% of outstanding common stock to the investor at a discount, and (2) a preferred stock purchase agreement for an undisclosed amount of Series P Non-Convertible Preferred Stock redeemable into common shares. The Company also amended its bylaws via Item 5.03. Combined, these transactions are highly dilutive to existing common shareholders, with the ELOC alone capable of issuing nearly 20% of the float, and the preferred stock adding further dilution upon redemption. With a market cap of only $2M, this represents a massive potential increase in share count, signaling severe financial distress and dependency on external capital.
Actionable Insight
The combination of a large ELOC and a new preferred stock issuance signals severe cash burn and an inability to raise capital on favorable terms. Traders should expect intense downward pressure on JAGX as the ELOC investor sells shares into the market at a 5% discount. Monitor for any registration statement filing for resale of the shares, which would trigger the selling. Given historical performance where neutral reports yielded -14% average T+5 returns and short reports were correct on alpha, a bearish stance is warranted. The $2M market cap suggests any meaningful draw on the ELOC will be extremely dilutive.
Key Facts
- Jaguar Health entered a Common Stock Purchase Agreement (ELOC) with C/M Capital Partners for up to $40M or 19.99% of outstanding common stock, whichever is lower.
- The Company also entered a Preferred Stock Purchase Agreement for Series P Non-Convertible Preferred Stock, redeemable into common shares or pre-funded warrants.
- Commitment shares of $800,000 worth of common stock (valued at VWAP purchase price) will be issued to the ELOC investor as compensation.
- The ELOC includes Fixed Purchases (up to $1.5M per draw), VWAP Purchases, and Additional VWAP Purchases (up to $4.5M aggregate per day), all at a 5% discount to market.
- A Floor Price of $1.10 per share is set for purchases under the ELOC, far above the current price given the $2M market cap.
- The preferred stock agreement includes a $20,000 non-accountable fee to the investor, withheld from the purchase price.
- The Company amended its bylaws (Item 5.03), though specific changes are not detailed in the filing.
- Market cap of $2M makes these financings extremely large relative to the company's size, implying massive dilution.
Financial Impact
Potentially massive dilution: the ELOC alone can increase the share count by up to 19.99% (approx. 19.99% of current float) at deeply discounted prices (5% below market), plus an unknown number of shares from the preferred stock redemption. The $800k commitment shares further dilute existing holders.
Risk Factors
- Severe dilution from the ELOC could crush the stock price as the investor sells discounted shares.
- Preferred stock redemption adds further overhang of common shares.
- The company's ability to remain listed on Nasdaq is at risk given the tiny market cap and dilutive financings.
- Historical filing reports on JAGX show a negative average alpha of -17% at T+20, confirming the pattern of value destruction.
Market Snapshot
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-266770 |
| Document: d570985dex103.htm | 0001193125-26-266770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
8-K
| $2.74 awaiting T+1 | awaiting T+1 | — | $2.69 (+1.82%) |
|
Jun 8, 2026
4d ago
|
8-K
| $2.60 awaiting T+1 | awaiting T+1 | — | $2.69 (+3.66%) |
|
Jun 2, 2026
10d ago
|
8-K
| $2.92 $3.05 | ▼ −4.45% | ▼ −4.05% | $2.69 (+7.88%) |
|
May 29, 2026
14d ago
|
DEFA14A
| $3.27 $3.22 | ▼ −1.53% | ▼ −1.67% | $2.69 (−17.74%) |
|
May 27, 2026
17d ago
|
8-K
| $3.19 $3.29 | ▲ +3.13% | ▲ +2.58% | $2.69 (−15.67%) |
|
May 22, 2026
21d ago
|
8-K
| $3.11 $3.19 | ▼ −2.57% | ▼ −2.56% | $2.69 (+13.50%) |
|
May 19, 2026
24d ago
|
8-K
| $3.67 $3.47 | ▼ −5.45% | ▼ −5.64% | $2.69 (−26.70%) |
|
May 6, 2026
5w ago
|
DEFA14A
| $2.82 $2.98 | ▲ +5.67% | ▲ +6.00% | $2.69 (−4.61%) |
|
May 4, 2026
5w ago
|
8-K
| $3.25 $3.01 | ▲ +7.38% | ▲ +8.18% | $2.69 (+17.23%) |
|
Apr 27, 2026
6w ago
|
8-K
| $9.80 $0.2410 | ▲ +97.54% | ▲ +97.06% | $2.69 (+72.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access